CD8A and neoplasm: Through the T cell-based anti-tumor mechanisms investigation, compared to siPD-L1 or 1MT control group, Co-CHL treatment contributed to more numbers of intratumoral CD8+ T cells, and higher CD8+/CD4+ T-cell ratio, resulting in stronger tumor regression and higher therapeutic efficacy.